Madrigal Pharmaceuticals (MDGL) 8-K Summary

This Form 8-K, filed November 4, 2025, announces the release of quarterly financial results for the period ended September 30, 2025.

• Material Event: Issuance of a press release detailing Q3 2025 financial performance.
• Investor Action: Investors must review Exhibit 99.1 (the accompanying press release) for specific financial metrics, revenue, earnings, and operational updates, as they are not detailed in the 8-K body.
• Filing Status: The information furnished under Item 2.02 is not deemed officially “filed” under S